Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ITGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ITGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ITGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017043 | Oral cavity | OSCC | formation of primary germ layer | 65/7305 | 121/18723 | 7.08e-04 | 3.90e-03 | 65 |
GO:00107623 | Oral cavity | OSCC | regulation of fibroblast migration | 24/7305 | 36/18723 | 7.18e-04 | 3.95e-03 | 24 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00903173 | Oral cavity | OSCC | negative regulation of intracellular protein transport | 27/7305 | 42/18723 | 8.00e-04 | 4.29e-03 | 27 |
GO:00323874 | Oral cavity | OSCC | negative regulation of intracellular transport | 35/7305 | 58/18723 | 8.06e-04 | 4.32e-03 | 35 |
GO:0033628 | Oral cavity | OSCC | regulation of cell adhesion mediated by integrin | 30/7305 | 48/18723 | 8.31e-04 | 4.41e-03 | 30 |
GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
GO:00072298 | Oral cavity | OSCC | integrin-mediated signaling pathway | 58/7305 | 107/18723 | 1.00e-03 | 5.20e-03 | 58 |
GO:00350245 | Oral cavity | OSCC | negative regulation of Rho protein signal transduction | 16/7305 | 22/18723 | 1.40e-03 | 6.79e-03 | 16 |
GO:003003819 | Oral cavity | OSCC | contractile actin filament bundle assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:004314919 | Oral cavity | OSCC | stress fiber assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:00300328 | Oral cavity | OSCC | lamellipodium assembly | 41/7305 | 72/18723 | 1.53e-03 | 7.31e-03 | 41 |
GO:20002092 | Oral cavity | OSCC | regulation of anoikis | 17/7305 | 24/18723 | 1.59e-03 | 7.56e-03 | 17 |
GO:001063418 | Oral cavity | OSCC | positive regulation of epithelial cell migration | 88/7305 | 176/18723 | 1.91e-03 | 8.94e-03 | 88 |
GO:003223119 | Oral cavity | OSCC | regulation of actin filament bundle assembly | 56/7305 | 105/18723 | 1.99e-03 | 9.23e-03 | 56 |
GO:19901388 | Oral cavity | OSCC | neuron projection extension | 86/7305 | 172/18723 | 2.13e-03 | 9.80e-03 | 86 |
GO:006104116 | Oral cavity | OSCC | regulation of wound healing | 69/7305 | 134/18723 | 2.19e-03 | 9.95e-03 | 69 |
GO:00434916 | Oral cavity | OSCC | protein kinase B signaling | 103/7305 | 211/18723 | 2.29e-03 | 1.02e-02 | 103 |
GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
GO:00703735 | Oral cavity | OSCC | negative regulation of ERK1 and ERK2 cascade | 43/7305 | 78/18723 | 2.80e-03 | 1.22e-02 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB1 | SNV | Missense_Mutation | | c.2050N>G | p.Gln684Glu | p.Q684E | P05556 | protein_coding | tolerated(0.27) | benign(0.006) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | | c.445A>C | p.Met149Leu | p.M149L | P05556 | protein_coding | deleterious(0.03) | benign(0.398) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | SNV | Missense_Mutation | | c.826T>C | p.Phe276Leu | p.F276L | P05556 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | rs758287253 | c.1474N>T | p.Asn492Tyr | p.N492Y | P05556 | protein_coding | deleterious(0) | possibly_damaging(0.494) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.1500_1501insCAGCTCTAATCCTCATAACAGTCCTGTGCCTAGAA | p.Glu501GlnfsTer3 | p.E501Qfs*3 | P05556 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.560_561insCTCTAGATGACCTTCTTTGATTTTAGAGGCCTCTTAGTGG | p.Val188SerfsTer3 | p.V188Sfs*3 | P05556 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.1982N>A | p.Cys661Tyr | p.C661Y | P05556 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ITGB1 | SNV | Missense_Mutation | | c.337N>G | p.Gln113Glu | p.Q113E | P05556 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITGB1 | SNV | Missense_Mutation | novel | c.1480G>C | p.Gly494Arg | p.G494R | P05556 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.2216N>C | p.Gly739Ala | p.G739A | P05556 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | FIRATEGRAST | FIRATEGRAST | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | 131I-radretumab | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL2108061 | VOLOCIXIMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | JSM 6427 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 385612210 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1201607 | NATALIZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | F200 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | R1295 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |